Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
Find a Broker »
- li>
- li>
- li>
- li>
- li>
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.49 | 0.42 | 15.59 |
| EPS, GAAP | 0.48 | 0.42 | 0.42 |
| Consensus Estimate | 0.49 | 0.52 | -7.18 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 1.60 | 1.81 | -11.86 |
| EPS, GAAP | 1.64 | 1.77 | -7.70 |
| Consensus Estimate | 1.93 | 1.97 | -1.78 |
| GILD | Industry Average | |
| P/E (TTM) | 27.78 | NA |
| P/E (Forward) | 23.87 | NA |
| PEG Ratio | 0.87 | 2.19 |
| Price/Sales | 7.52 | 18.50 |
| Beta | 0.68 | 0.70 |
| 5:25 PM | 3/22/2013 | Idenix Loses 1st-Stage of Drug Compounds Patent Case |
| 9:18 AM | 3/22/2013 | Gentium Gets Negative Opinion From CHMP; Biogen, Others Get Positive Opinions |
| 3/29/2013 | Quarterly Winners: Transports, Biotech, MLPs and … Spinoffs (Barrons.com) |
| 3/27/2013 | 24/7 Wall St. Closing Bell — March 27, 2013: Markets Close Mixed After Low Start (VMW, GOOG, AOL, GIS, ORCL, MFRM, SAI, XONE, PAYX, SNX, TXI, END, FINL, GME, MOS, BBRY, WGO, CLF, FB, GILD) (24/7 Wall St) |
| 3/25/2013 | Gilead Has an Edge on Indenix in Suit (Barrons.com) |
| 3/25/2013 | Top Stocks to Buy from the Merrill Lynch Core Portfolio (BAC, SPY, V, JPM, GILD, OXY, HON, HD, WMT) (24/7 Wall St) |
| 3/25/2013 | A Rewarding Development (Barrons.com) |
| 3/14/2013 | Top Analyst Upgrades and Downgrades (AMZN, DOX, AAPL, MT, CINF, ETFC, EBAY, GILD, HTWR, IPAR, SNDK, VMW, WFC) (24/7 Wall St) |
| 3/12/2013 | UBS Picks the Eight Top Stocks to Buy Now (F, HD, SBUX, GILD, MCK, MYL, CMI, LLTC) (24/7 Wall St) |
| 3/8/2013 | Pfizer Stops Developing Hepatitis C Drug (WSJ.com) |